Parameter
| Biomarker | MRD | Full name | minimal residual disease | Molecular Type | Cell/nucleic acid |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Efficacy evaluation and prognosis | ||
| Disease | Multiple Myeloma (MM) | Disease Subtypes | / | ||
| Organ | Bone marrow, Peripheral blood | Test Sample / Technology Platform | marrow、peripheral blood | ||
| Pathobiological Mechanisms | The residual minimal residual malignant plasma cells after treatment are the seeds of recurrence | ||||
| Clinical Availability Status | Clinical validation/trial application (Recommended by IMWG, as a partial clinical trial endpoint) | ||||
| Notes and Dynamics | Continuous MRD-negative status (≥1 year) is associated with a 5-year PFS rate exceeding 70%; dynamic MRD monitoring (transition to positivity) holds greater prognostic value than single testing; combined PET-CT can prevent missed diagnosis of extramedullary MRD. | ||||